Literature DB >> 10231639

Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts.

L B Schwartz1, J Moawad, E C Svensson, R L Tufts, S L Meyerson, D Baunoch, J M Leiden.   

Abstract

PURPOSE: Inappropriate or excessive vascular smooth muscle cell proliferation leads to the development of occlusive lesions in up to 50% of vein grafts. The purpose of this study was to test the hypothesis that induced overexpression of a cytostatic nonphosphorylatable form of the retinoblastoma protein (DeltaRb) would attenuate neointimal thickening in experimental vein grafts.
METHODS: A replication-deficient adenovirus vector that encoded a nonphosphorylatable, constitutively active form of DeltaRb was constructed (AdDeltaRb) and contained an NH2-terminal epitope tag from the influenza hemagglutinin molecule (HA). Forty-eight male New Zealand white rabbits underwent surgical exposure of the external jugular vein for transfection with either 3 x 10(10) plaque-forming units/mL AdDeltaRb (n = 16), 3 x 10(10) plaque-forming units/mL control adenovirus (AdBglII, n = 15), or vehicle (n = 17) for 10 minutes at 120 mm Hg. After vector exposure, the vein was excised and interposed end-to-end into the carotid circulation. After 5 days, 12 grafts (four from each group) were excised and assayed for genomic DeltaRb DNA with the polymerase chain reaction or for hemagglutinin molecule expression and localization with immunohistochemistry. The remainder of the grafts (n = 36) were perfusion-fixed after 4 weeks, and 5 microm sections prepared for digital planimetric analysis.
RESULTS: Polymerase chain reaction results identified the DeltaRb gene only in the grafts that were transfected with AdDeltaRb. Immunohistochemical analysis results revealed transgene expression in most of the endothelial cells and in many of the smooth muscle cells. After 4 weeks, the grafts that were exposed to AdDeltaRb exhibited a 22% reduction in neointimal thickness (vehicle, 77 +/- 7 microm; AdBglII, 75 +/- 5 microm; AdDeltaRb, 60 +/- 5 microm; P =.05), and medial thickness, luminal diameter, and other parameters were unchanged (medial thickness: vehicle, 72 +/- 10 microm; AdBglII, 85 +/- 7 microm; AdDeltaRb, 69 +/- 9 microm; P = NS; luminal diameter: vehicle, 4.5 +/- 0.2 mm; AdBglII, 4.4 +/- 0.2 mm; AdDeltaRb, 4.7 +/- 0.1 mm; P = NS).
CONCLUSION: With this delivery system, adenoviral-mediated gene transfer is highly efficient and induced overexpression of DeltaRb leads to a reduction in vein graft neointimal thickening.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231639     DOI: 10.1016/s0741-5214(99)70215-6

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

Review 1.  Gene therapy for vein graft disease.

Authors:  D G Cable; H V Schaff
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 2.  Gene therapy for vein grafts.

Authors:  M J Mann
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

3.  Endothelial retinoblastoma protein reduces abdominal aortic aneurysm development via promoting DHFR/NO pathway-mediated vasoprotection.

Authors:  Yu Cao; Da Xiong; Ruize Kong; Guolin Dai; Minghua Zhong; Li Li; Jinping Zhang; Lihong Jiang; Hongrong Li
Journal:  Mol Cell Biochem       Date:  2019-06-18       Impact factor: 3.396

4.  A Rabbit Model of Durable Transgene Expression in Jugular Vein to Common Carotid Artery Interposition Grafts.

Authors:  Lianxiang Bi; Bradley K Wacker; David A Dichek
Journal:  J Vis Exp       Date:  2018-09-10       Impact factor: 1.355

5.  A Rabbit Model for Testing Helper-Dependent Adenovirus-Mediated Gene Therapy for Vein Graft Atherosclerosis.

Authors:  Lianxiang Bi; Bradley K Wacker; Emma Bueren; Ervin Ham; Nagadhara Dronadula; David A Dichek
Journal:  Mol Ther Methods Clin Dev       Date:  2017-09-28       Impact factor: 6.698

6.  Gene Therapy for Cardiovascular Disease.

Authors:  Kate L. Dishart; Lorraine M. Work; Laura Denby; Andrew H. Baker
Journal:  J Biomed Biotechnol       Date:  2003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.